-+ 0.00%
-+ 0.00%
-+ 0.00%

Santhera's Partner Seeks Marketing Permit in South Korea for Duchenne Muscular Dystrophy Treatment

MT Newswires·10/23/2026 01:59:07
Listen to the news
01:59 AM EDT, 10/23/2026 (MT Newswires) -- Santhera Pharmaceuticals (SANN.SW) said its licensing partner filed a marketing application in South Korea for Duchenne muscular dystrophy treatment Agamree, or vamorolone. The specialty pharmaceutical company said Friday that Nxera Pharma submitted the application to South Korea's Ministry of Food and Drug Safety, following orphan drug and fast-track designations for Agamree in June. Nxera is looking to commercially launch Agamree in South Korea in 2028, following expected market authorization in 2027.